QNTM

Quantum Biopharma Subordinate Voting SharesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$7.50

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$3.40

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$1.30

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-03

AI commentary

Headline tone is positive because of FDA Phase 2 clearance, lower expenses, and the reported runway, but the evidence remains low-coverage and company-driven. The stock's August rally reversed into early September, while analyst revisions and social coverage are unavailable. Deterministic signals remain negative for the next 5 to 120 days, so this is a monitoring setup rather than a high-conviction rerating call.

RankAlpha Sentiment Codex - 2026-09-03

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-08-14eventQ2 cost reduction and liquidity updateMedium impact

Q2 operating expenses fell 53% year over year and six-month operating cash use fell 44%. Cash, cash equivalents, and digital assets totaled approximately $9.5 million at June 30, with management projecting runway to at least October 2027 under stated assumptions. [#SEC-6K-2026-08-14]

2026-12-02catalystPost-print price follow-through remains fragileHigh impact

The shares rose 17.65% on August 14 but closed lower on August 17, 18, and 20; the September 2 anchor price was $3.08 versus $3.80 on August 14. This suggests the regulatory and earnings headlines have not produced durable follow-through, without proving causality. [#MARKET-DATA-2026-09-02]

2027-09-03catalystLucid-MS Phase 2 trial start-up and enrollmentHigh impact

FDA approval of the Lucid-MS IND cleared a randomized, placebo-controlled Phase 2 trial in progressive MS; site selection is underway and enrollment is expected to begin quickly. Execution, enrollment, and eventual efficacy remain unproven. [#SEC-6K-2026-08-14]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-03 • Updated nightlySource: Internal modelMethodology